Report : Asia Pacific Corneal Transplantation Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Penetrating Keratoplasty, Descemet Membrane Endothelial Keratoplasty (DMEK), Descemet Stripping Endothelial Keratoplasty (DSEK), Corneal Limbal Stem Cell Transplant, and Others), Indication (Fungal Corneal Ulcer, Fuchs Dystrophy, Keratoconus, Keratitis, and Others), and End User (Hospitals, Eye Clinic, and Ambulatory Surgical Centers)
Hospitals Segment to Dominate APAC Corneal Transplantation Market During 2021–2028
According to a new market research study on “APAC Corneal Transplantation Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type, Indication, and End User” is expected to reach US$ 117.93 million by 2028 from US$ 69.52 million in 2021. The market is estimated to grow at a CAGR of 7.8% from 2021 to 2028. The report provides trends prevailing in the APAC corneal transplantation market along with the drivers and restraints pertaining to the market growth. Initiation of high-tech products for transplantation and growing initiatives from various organizations and governments are the major factor driving the growth of the APAC corneal transplantation market. However, risks associated with corneal transplantation and shortage of donor corneas hinders the growth of APAC corneal transplantation market.
The APAC corneal transplantation market is segmented based on type, indication, end user, and country. Based on type, the APAC corneal transplantation market is segmented into penetrating keratoplasty, descemet membrane endothelial keratoplasty (DMEK), descemet stripping endothelial keratoplasty (DSEK), corneal limbal stem cell transplant, and others. The penetrating keratoplasty segment dominated the APAC corneal transplantation market in 2020 and descemet membrane endothelial keratoplasty (DMEK) segment is expected to be fastest growing during forecast period. Based on indication, the APAC corneal transplantation market is segmented into fungal corneal ulcer, fuchs dystrophy, keratoconus, keratitis, and others. The fuchs dystrophy segment dominated the APAC corneal transplantation market in 2020 and same segment is expected to be fastest growing during forecast period. Based on end user, the APAC corneal transplantation market is segmented into hospitals, eye clinic, and ambulatory surgical centers. The hospitals segment dominated the APAC corneal transplantation market in 2020 and ambulatory surgical centers segment is expected to be fastest growing during forecast period. Based on country, the APAC corneal transplantation market has been segmented into China, India, Japan, South Korea, Australia, and rest of APAC.
Alcon Inc.; Aurolab; Corneat Vision; EYEMEDICS; Florida Lions Eye Bank; and Keramed, Inc. are among the leading companies in the APAC corneal transplantation market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2022, Alcon, the global leader in eye care dedicated to helping people see brilliantly, has announced the closing of its previously announced acquisition of Ivantis, developer of the novel Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surgery.
Contact Person: Sameer Joshi
Email Id: email@example.com